Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļQNTM
āļāļ·āđāļāļāļĢāļīāļĐāļąāļQuantum Biopharma Ltd
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 29, 2018
āļāļĩāļāļĩāđāļKotra (Lakshmi P)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ- -
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļMay 29
āļāļĩāđāļāļĒāļđāđ55 University Ave. , Suite 1003
āđāļĄāļ·āļāļTORONTO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻCanada
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđM5J 2H7
āđāļāļĢāļĻāļąāļāļāđ14168548884
āđāļ§āđāļāđāļāļāđhttps://www.quantumbiopharma.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļQNTM
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 29, 2018
āļāļĩāļāļĩāđāļKotra (Lakshmi P)
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
Mr. Donal Carroll, CPA
Chief Financial Officer
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Mr. Adnan Bashir
Independent Director
Dr. Lakshmi P. Kotra, Ph.D.
Dr. Lakshmi P. Kotra, Ph.D.
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Mr. Joseph L. Romano
Director
Dr. Eric Hoskins, M.D.
Independent Director
Mr. Michael (Zappy) Zapolin
Mr. Michael (Zappy) Zapolin
Independent Director
Dr. Andrzej Chruscinski, M.D., Ph.D.
Dr. Andrzej Chruscinski, M.D., Ph.D.
Vice President - Clinical and Scientific Affairs
Vice President - Clinical and Scientific Affairs
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
Mr. Donal Carroll, CPA
Chief Financial Officer
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Mr. Adnan Bashir
Independent Director
Dr. Lakshmi P. Kotra, Ph.D.
Dr. Lakshmi P. Kotra, Ph.D.
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ